Outcomes of Third-Line Trastuzumab Deruxtecan in a Patient with De Novo Stage 4 HER2-Positive Gastric Adenocarcinoma with Enteroblastic Differentiation: A Case Report

Outcomes of Third-Line Trastuzumab Deruxtecan in a Patient with De Novo Stage 4 HER2-Positive Gastric Adenocarcinoma with Enteroblastic Differentiation: A Case Report

This case report describes the treatment of a patient diagnosed with de novo stage 4 human epidermal growth factor 2 (HER2)-positive gastric adenocarcinoma with enteroblastic differentiation (GAED), a rare and aggressive form of gastric cancer characterized by a tubulopapillary growth pattern and en...

Full description

Bibliographic Details
Main Author: Roger Kai-Cheong Ngan
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Life
Subjects:
antibody-drug conjugate
case reports
gastric cancer
immune checkpoint inhibitors
trastuzumab
Online Access:https://www.mdpi.com/2075-1729/13/9/1851

Internet

https://www.mdpi.com/2075-1729/13/9/1851

Similar Items